Contract research organization Sygnature Discovery has appointed Dr. David Witty as its Chief Scientific Officer (CSO).
Sygnature Discovery, a U.K.-based preclinical contractor, is pumping 3.75 million pounds sterling ($4.6 million) into Azenta Life Sciences’ compound management storage system that will allow it to store customer libraries.
The collaboration aims to explore the incorporation of human iPSC-derived microglia into high-content imaging in vitro screening workflows. Human iPSC-derived cells are stem cells derived from patient donors that are a powerful tool in biomedical research due to their ability to differentiate into various cell types found in the human body. Microglia are neuro-inflammatory cells that constitute ~10% of the brain’s cell population and are a key therapeutic target in the development of adequate treatments for Alzheimer’s Disease and other neurodegenerative conditions.
Sygnature Discovery, a drug discovery CRO, acquired NuChem Sciences, adding integrated drug discovery phase services.